Product Recall and International Alerts in Panama: Prior Authorisation Required
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
In Panama, even a voluntary recall needs approval first. Article 58 of DE 490 provides that where a manufacturer or importer intends a total or partial voluntary withdrawal (retiro voluntario) of a product that presents a risk to patient health, it must notify DNDM of the product and of the complementary mechanism, and must obtain prior authorisation (autorización previa) before carrying out the recall. The notification must contain at least four items: the device name, model, lot or serial number and expiry date where applicable; the reason for the recall and the documents supporting that decision; the traceability information for the device within Panama; and the actions to be taken, including the expected recall timing and the final disposal. The second paragraph of the same article adds that any notice issued by the manufacturer or importer to users concerning any aspect of the safety or performance of the device must also be notified to DNDM. International alerts follow Article 59: importers must notify DNDM, within the time it sets, of alerts issued by an overseas parent company or by global health bodies that concern devices they sell in Panama. Article 60 then assigns DNDM the tracking, assessment, management and publication of international safety reports and alerts.
2. Legal basis
The recall and alert provisions sit at the point where product safety, distribution records and administrative authorisation meet. The table sets out the authorisation requirement, the four mandatory content items, the separate treatment of user notices, the international alert channel and the enforcement provisions that apply when notification is late or absent.
| Decreto Ejecutivo No. 490 (2019-10-04, Gaceta 28875-A) | Article 58, first paragraph | Manufacturers and importers must notify DNDM of a total or partial voluntary withdrawal together with the complementary mechanism; prior DNDM authorisation is required before the recall |
| Same | Article 58, second paragraph | Notices to users concerning the safety or performance of the device, directly or indirectly, must be notified to DNDM |
| Same | Article 58, third paragraph, item 1 | Notification must include at least the device name, model, lot or serial number and expiry date where applicable |
| Same | Article 58, third paragraph, item 2 | The reason for the recall and the documents supporting the decision |
| Same | Article 58, third paragraph, item 3 | Traceability information for the device within the country |
| Same | Article 58, third paragraph, item 4 | Actions to be taken, including the expected recall timing and the final disposal |
| Same | Article 59 | Importers must notify DNDM, within the time it sets, of international alerts issued by an overseas parent or a global health body concerning devices they sell in Panama |
| Same | Article 60 | DNDM tracks, assesses, manages and publishes safety reports and alerts issued by international health bodies on devices already on the national market |
| Same | Article 52.3 g | The vigilance department manages the tracking, assessment and handling of international safety reports, alerts and reports on devices already in the country |
| Same | Article 52.7 a | Manufacturers must notify DNDM of events, incidents and international alerts relating to the devices they sell |
| Same | Article 52.6 d and e | Suppliers must take preventive or corrective measures immediately, and must notify the manufacturer or importer of events or incidents occurring in the country |
| Same | Article 63 | Where a serious adverse event occurs despite correct use, commissioning and maintenance, DNDM may order seizure or suspension and prohibit or restrict use until the investigation ends; quarantine rules to be issued |
| Ley No. 90 (2017-12-26, Gaceta 28433-B) | Article 35 item 2 | Deliberate concealment or failure to notify in time alerts, voluntary recalls, adverse events and adverse incidents is a minor offence |
| Same | Article 36 item 2 | Obstructing an investigation or inspection is a serious offence |
| Same | Article 44 | Three fine bands: minor from B/.500.00; serious from B/.5,001.00; very serious from B/.50,001.00 |
3. Expert insights
Insight 1: approval before action is the sharpest procedural difference from other markets. The closing sentence of the first paragraph states that proceeding to the withdrawal requires prior authorisation from the National Directorate of Medical Devices. In most markets a voluntary recall is a company decision notified afterwards; Panama converts it into an administrative permission. The common practice of issuing a customer notice and reporting to the regulator later is therefore not lawful here, and the second paragraph closes the alternative route by bringing the user notice itself within the notification duty.
Insight 2: the traceability item forces importers to hold distribution records. The notification must contain the traceability of the device within Panama. This links the recall obligation directly to routine distribution records: without a lot-to-customer mapping the third item cannot be completed, and without a complete notification the prior authorisation will not issue. For companies working through distributors, this turns the question of whether to keep a flow ledger from a management preference into a legal precondition.
Insight 3: the fourth item writes the closure of the recall into the text. The notification must state the expected recall timing and the final disposal. The first allows DNDM to monitor progress; the second prevents devices from returning to the market through refurbishment or resale. When preparing the Article 58 notification, the final disposal plan has to be settled at submission and cannot be left open.
Insight 4: the duty holder for international alerts is the importer, which is narrower than Article 58. Article 59 places the duty to receive alerts from an overseas parent or a foreign health body and pass them to DNDM on the importer alone, while Article 52.7.a separately requires the manufacturer to notify DNDM of international alerts relating to its devices. The combined effect is that a foreign manufacturer needs a local importer able to receive and willing to carry the notification duty; otherwise the alert chain breaks in the middle.
4. Practical recommendations
- Rewrite the recall procedure as three steps: authorisation, execution, closure. Prepare the four items under Article 58 and apply for authorisation; withdraw only once authorisation is granted; then report closure against the expected timing and final disposal.
- Build the lot-to-customer ledger now. The third item requires domestic traceability, so the ledger must cover lot or serial number, recipient, quantity and date, and align with the twelve import invoice items under Article 27.
- Write the alert forwarding duty and deadline into the proveedor agreement. Specify how quickly the local importer must forward an alert issued by the overseas parent or a foreign authority, and who bears responsibility for a missed forwarding.
- Send user notices to DNDM at the same time. Any notice concerning safety or performance falls under the second paragraph and should be notified when issued, not afterwards.
- Treat late notification as a minor offence. Article 35.2 of Ley 90 with Article 44.1 gives a fine starting at B/.500.00; obstruction escalates to a serious offence starting at B/.5,001.00.
5. Verification checklist
- □ Recall procedure rewritten with prior DNDM authorisation as the first step under Article 58
- □ Four-item notification template in place: identification and expiry, reason with supporting documents, domestic traceability, action plan with timing and final disposal
- □ Lot-to-customer ledger able to output domestic traceability on demand
- □ Simultaneous DNDM notification flow for user notices under the second paragraph of Article 58
- □ Importer agreement states the Article 59 alert forwarding duty and deadline
- □ Article 63 seizure, suspension and restriction powers flagged to management
- □ Minor offence exposure under Article 35.2 and serious offence exposure under Article 36.2 recorded
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Panamanian market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us